GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pfenex Inc (AMEX:PFNX) » Definitions » Beneish M-Score

Pfenex (Pfenex) Beneish M-Score : -2.41 (As of May. 12, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Pfenex Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.41 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Pfenex's Beneish M-Score or its related term are showing as below:

PFNX' s Beneish M-Score Range Over the Past 10 Years
Min: -5.22   Med: -2.2   Max: 6.47
Current: -2.41

During the past 8 years, the highest Beneish M-Score of Pfenex was 6.47. The lowest was -5.22. And the median was -2.20.


Pfenex Beneish M-Score Historical Data

The historical data trend for Pfenex's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pfenex Beneish M-Score Chart

Pfenex Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19
Beneish M-Score
Get a 7-Day Free Trial -5.22 2.53 -3.23 -1.30 -0.11

Pfenex Quarterly Data
Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.78 6.47 -0.11 -2.20 -2.41

Competitive Comparison of Pfenex's Beneish M-Score

For the Biotechnology subindustry, Pfenex's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pfenex's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pfenex's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Pfenex's Beneish M-Score falls into.



Pfenex Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Pfenex for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.2041+0.528 * 0.7646+0.404 * 0.7021+0.892 * 2.1948+0.115 * 1.405
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.5304+4.679 * -0.051205-0.327 * 0.8738
=-2.46

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Jun20) TTM:Last Year (Jun19) TTM:
Total Receivables was $1.51 Mil.
Revenue was 0.781 + 0.682 + 21.905 + 15.248 = $38.62 Mil.
Gross Profit was 0.101 + 0.342 + 20.851 + 14.105 = $35.40 Mil.
Total Current Assets was $64.53 Mil.
Total Assets was $85.77 Mil.
Property, Plant and Equipment(Net PPE) was $12.11 Mil.
Depreciation, Depletion and Amortization(DDA) was $1.87 Mil.
Selling, General, & Admin. Expense(SGA) was $19.56 Mil.
Total Current Liabilities was $8.97 Mil.
Long-Term Debt & Capital Lease Obligation was $2.50 Mil.
Net Income was -10.331 + -10.151 + 9.266 + 3.082 = $-8.13 Mil.
Non Operating Income was 0.003 + 0.05 + 0.04 + 0.055 = $0.15 Mil.
Cash Flow from Operations was -5.326 + -8.656 + 18.774 + -8.682 = $-3.89 Mil.
Total Receivables was $3.37 Mil.
Revenue was 2.811 + 7.862 + 3.351 + 3.57 = $17.59 Mil.
Gross Profit was 1.692 + 6.296 + 2.252 + 2.091 = $12.33 Mil.
Total Current Assets was $46.86 Mil.
Total Assets was $64.12 Mil.
Property, Plant and Equipment(Net PPE) was $7.53 Mil.
Depreciation, Depletion and Amortization(DDA) was $1.75 Mil.
Selling, General, & Admin. Expense(SGA) was $16.80 Mil.
Total Current Liabilities was $9.74 Mil.
Long-Term Debt & Capital Lease Obligation was $0.07 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(1.509 / 38.616) / (3.369 / 17.594)
=0.039077 / 0.191486
=0.2041

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(12.331 / 17.594) / (35.399 / 38.616)
=0.700864 / 0.916693
=0.7646

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (64.526 + 12.107) / 85.773) / (1 - (46.856 + 7.534) / 64.122)
=0.10656 / 0.151773
=0.7021

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=38.616 / 17.594
=2.1948

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(1.748 / (1.748 + 7.534)) / (1.874 / (1.874 + 12.107))
=0.188321 / 0.134039
=1.405

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(19.556 / 38.616) / (16.798 / 17.594)
=0.506422 / 0.954757
=0.5304

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((2.496 + 8.971) / 85.773) / ((0.072 + 9.738) / 64.122)
=0.13369 / 0.15299
=0.8738

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-8.134 - 0.148 - -3.89) / 85.773
=-0.051205

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Pfenex has a M-score of -2.46 suggests that the company is unlikely to be a manipulator.


Pfenex (Pfenex) Business Description

Traded in Other Exchanges
N/A
Address
10790 Roselle Street, San Diego, CA, USA, 92121
Pfenex Inc is a clinical-stage biotechnology company involved in the development of protein production and bioanalytic technology. The biosimilars portfolio include PF582, for the treatment of patients with retinal diseases; PF530, designed to treat patients with multiple sclerosis; and PF708, to treat osteoporosis patients at high risk of fractures. Its vaccine portfolio consists of Px563L, a novel anthrax vaccine candidate to meet U.S. government demand, funded by the U.S. Department of Health and Human Services, through the Biomedical Advanced Research and Development Authority.
Executives
Ligand Pharmaceuticals Inc 10 percent owner 3911 SORRENTO VALLEY BLVD, SUITE 110, SAN DIEGO CA 92121
Phillip M Schneider director GEN-PROBE INCORPORATED, 10210 GENETIC CENTER DRIVE, SAN DIEGO CA 92121
Jason Grenfell-gardner director 105 LINCOLN AVENUE BUENA NJ 08310
Patrick K. Lucy officer: Chief Business Officer C/O PFENEX INC., 10790 ROSELLE STREET, SAN DIEGO CA 92121
Robin Campbell director C/O PFENEX INC., 10790 ROSELLE STREET SAN DIEGO CA 92121
Magda Marquet director ALTHEADX INC., 3550 DUNHILL STREET, SAN DIEGO CA 92121
John Mack Taylor director C/O PFENEX, INC. 10790 ROSELLE STREET SAN DIEGO CA 92121
Evert B. Schimmelpennink director, officer: See Remarks C/O PFENEX INC., 10790 ROSELLE STREET, SAN DIEGO CA 92121
Shawn Scranton officer: Chief Operating Officer C/O PFENEX INC 10790 ROSELLE STREET SAN DIEGO CA 92121
Martin Brenner officer: Chief Scientific Officer C/O PFENEX INC., 10790 ROSELLE STREET, SAN DIEGO CA 92121
Lorianne Masuoka director C/O PFENEX INC. 10790 ROSELLE STREET SAN DIEGO CA 92121
Newtyn Management, Llc 10 percent owner 60 EAST 42ND STREET, 9TH FLOOR, NEW YORK NY 10165
Weiss Asset Management Lp 10 percent owner 222 BERKELEY STREET, 16TH FLOOR, BOSTON MA 02116
Andrew M Weiss 10 percent owner 222 BERKELEY STREET, 16TH FLOOR, BOSTON MA 02116
Wam Gp Llc 10 percent owner 222 BERKELEY STREET, 16TH FLOOR, BOSTON MA 02116

Pfenex (Pfenex) Headlines